|
|
ACM-CPG |
|
Vaxjo ID |
145 |
|
Vaccine Adjuvant Name |
ACM-CPG |
|
Adjuvant VO ID |
VO_0006106
|
|
Description |
An emulsion vaccine adjuvant that targets on TLR-agonist. It is a nucleic acid-based adjuvant for chemical nature |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Australia |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
amphiphilic block copolymer comprising poly(butadiene)-b-poly(ethylene glycol) and a cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane |
|
Storage |
ACM-CpG adjuvant is stored as liquid formulation at 2-8 °Celsius, avoid freeze-thawing |
|
Function |
Type: emulsion vaccine adjuvant. Target Receptor: Toll-like receptor 9 (TLR9). Induces Th1-biased immune profile. Innate Immune Activation, preferential uptake by APCs |
| References |
(Nallani, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=92]
Lam et al., 2021: Lam JH, Khan AK, Cornell TA, Chia TW, Dress RJ, Yeow WWW, Mohd-Ismail NK, Venkataraman S, Ng KT, Tan YJ, Anderson DE, Ginhoux F, Nallani M. Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine. ACS nano. 2021; 15(10); 15754-15770. [PubMed: 34618423].
Lam et al., 2022: Lam JH, Shivhare D, Chia TW, Chew SL, Sinsinbar G, Aw TY, Wong S, Venkataraman S, Lim FWI, Vandepapeliere P, Nallani M. Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine. ACS nano. 2022; 16(10); 16757-16775. [PubMed: 36223228].
|
|
